Related Experiment Videos
Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning
G Belcaro1, B M Errichi, P De Simone
1Microcirculation Laboratory, Università Abruzzese G.D'Annunzio, Chieti, Italy.
Insights
Preventing recurrent deep venous thrombosis (DVT) is crucial. Prophylactic treatment with indobufen significantly reduced thrombosis incidence and asymptomatic episodes over three years in DVT patients.
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Deep venous thrombosis (DVT) is a significant vascular condition.
- Recurrent DVT poses a risk for patients, often presenting asymptomatically.
- Understanding sequelae and effective prophylaxis is vital for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of indobufen prophylaxis in preventing recurrent DVT.
- To assess the incidence of recurrent thrombosis and asymptomatic episodes.
- To determine the long-term impact of prophylaxis on the deep venous system.
Main Methods:
- A randomized controlled trial involving 123 patients post-DVT.
- Patients were assigned to prophylactic indobufen treatment or a control group.
- Color duplex scanning (CDS) was used for monitoring over three years.
Main Results:
- Indobufen prophylaxis resulted in a 5% incidence of recurrent thrombosis versus 46% in controls.
- Asymptomatic recurrent DVT episodes were lower in the indobufen group (33.3%) compared to controls (62%).
- Indobufen demonstrated effectiveness in preventing recurrent thrombosis and venous system deterioration.
Conclusions:
- Recurrent DVT is common, frequently asymptomatic, and can be mistaken for initial episode sequelae.
- Prophylaxis with indobufen is an effective strategy to prevent recurrent DVT.
- Indobufen treatment helps avoid progressive deterioration of the deep venous system post-DVT.
Abstract:
After an episode of deep venous thrombosis (DVT) 123 patients were randomized into two groups: one was prophylactically treated with indobufen (60 patients), an oral antiplatelet agent, and one had no treatment (63) and acted as a control group. They were followed up for three years and scanned with color duplex scanning (CDS) every three months and any time that signs and symptoms suggested a new episode. In patients receiving indobufen the incidence of thrombosis was 5% in three years while it was significantly higher (46%) in the control group. Also 62% of the new episodes in the control group were asymptomatic (33.3% in the treated group). Results suggest that recurrent DVT is common, often asymptomatic, and confused with sequelae of the initial episode. The prophylaxis with indobufen is an effective measure in preventing recurrent thrombosis and avoiding the progressive deterioration of the deep venous system observed after deep venous thrombosis.